Touchlight, an innovation-driven Contract Development and Manufacturing Organisation (CDMO), today announced that its facility in Hampton UK has received GMP certification. As a result, Touchlight ...

Overview: In Uganda alone, frequent FMD outbreaks have resulted in losses amounting to millions annually. Between 2015 and ...

Here, the synthetic mRNA encoding tumour-associated or tumour-specific antigens can be delivered through autologous dendritic cells engineered with mRNA ex vivo or through formulated or non ...

LFGY is an actively managed ETF that seeks current income and capital appreciation via direct investments in a select portfolio of 15-30 crypto industry and technology (“Crypto”) companies. LFGY aims ...

Thrusting Cambridge-based life science business 4basebio has appointed an experienced executive to boost its global growth ...

An often-overlooked mechanism of gene regulation may be involved in the failure of antifungal drugs in the clinic, claims a ...

Researchers from the Leibniz Institute for Natural Product Research and Infection Biology discovered that RNA modifications ...

Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new ...

Importance of RNA modifications for the development of resistance in fungi raises hope for more effective treatment of fungal infections.

such as mRNA, structure-based antigen design and synthetic biology, will be key to ensuring we remain a leader in this field," said Barron.

Yahoo Finance's Brad Smith reviews Wednesday's trending stocks on Wealth. Moderna's (MRNA) price target slashed to $38 from $70 by Morgan Stanley (MS), implying an 11% potential upside based on ...